PHAT · Phathom Pharmaceuticals, Inc.
$11.64
-0.02 (-0.17%)
At close · Jul 29
Earnings today
Market Cap
$928.36M
Shares
79.76M
Phathom Pharmaceuticals, Inc. Earnings Call Transcripts
Every quarterly earnings call for Phathom Pharmaceuticals, Inc. (PHAT) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
·
$1.91M
−$82.85M
'24 Q1
24-05-09
·
$7.32M
−$91.45M
'24 Q2
24-08-08
·
$16.35M
−$85.58M
'24 Q3
24-11-07
·
$29.66M
−$74.45M
'24 Q4
25-03-06
▲1391.6%
$28.52M
−$94.32M
'25 Q1
25-05-01
▲439.4%
$39.50M
−$75.81M
'25 Q2
25-08-07
▲202.7%
$49.50M
−$29.97M
'25 Q3
25-10-30
▲94.1%
$57.58M
−$21.15M
'25 Q4
26-02-26
LATEST
▲104.4%
$58.30M
−$30.37M
'26 Q1
26-04-30
Earnings call
FY26 · Q2
2026-07-30
Phathom Pharmaceuticals – Second Quarter 2026 Earnings Conference Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-09
Goldman Sachs 47th Annual Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-06-03
Jefferies Global Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-04-30
Phathom Pharmaceuticals, Inc. Q1 FY2026 Earnings Call
Confident tone
New-to-Brand Prescription Share (NBRX)
Gastroenterology Strategy Execution
Total Prescription (TRX) and Refill Persistence
Revenue
$58.30M
▲ 104.4% YoY Diluted EPS
$-0.37
Gross margin
79.4%
Rev · 7q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-04-15
25th Annual Needham Virtual Healthcare Conference
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY25 · Q4
2026-02-26
Phathom Pharmaceuticals, Inc. Q4 FY2025 Earnings Call
Confident tone
Financial Performance and Guidance
Vaquesna Commercial Progress
Reimbursement and Access
Revenue
$57.58M*
▲ 94.1% YoY Gross margin
86.7%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-10-30
Phathom Pharmaceuticals, Inc. Q3 FY2025 Earnings Call
Confident tone
Sales Force Realignment
Prescription Metrics
Gastroenterology Strategic Shift
Revenue
$49.50M
▲ 202.7% YoY Diluted EPS
$-0.41
Gross margin
87.5%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-07
Phathom Pharmaceuticals, Inc. Q2 FY2025 Earnings Call
Confident tone
Sales force realignment toward gastroenterologists
Eosinophilic esophagitis (EoE) development
BlinkRx cash pay channel and access
Revenue
$39.50M
▲ 439.4% YoY Diluted EPS
$-1.05
Gross margin
87.2%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-01
Phathom Pharmaceuticals, Inc. Q1 FY2025 Earnings Call
Positive tone
Citizens Petition and exclusivity timeline
VOQUEZNA commercial launch and revenue growth
Manufacturing and tariffs
Revenue
$28.52M
▲ 1391.6% YoY Diluted EPS
$-1.31
Gross margin
86.9%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-06
Phathom Pharmaceuticals, Inc. Q4 FY2024 Earnings Call
Confident tone
VOQUEZNA commercial launch and growth momentum
Non-Erosive GERD approval inflection
Eosinophilic esophagitis (EoE) label expansion
Revenue
$29.66M*
Gross margin
87.1%
Rev · 3q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-07
Phathom Pharmaceuticals, Inc. Q3 FY2024 Earnings Call
Confident tone
VOQUEZNA commercial launch momentum
Guidance visibility for 2025
Non-Erosive GERD label expansion
Revenue
$16.35M
Diluted EPS
$-1.32
Gross margin
85.6%
Rev · 3q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-08
Phathom Pharmaceuticals, Inc. Q2 FY2024 Earnings Call
Confident tone
VOQUEZNA launch momentum
Patient testimonials and demand
Physician adoption / prescriber mix
Revenue
$7.32M
Diluted EPS
$-1.56
Gross margin
81.2%
Rev · 2q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-09
Phathom Pharmaceuticals, Inc. Q1 FY2024 Earnings Call
Confident tone
BlinkRx reliance and cash-pay dynamics
Nonerosive GERD label expansion opportunity
Direct-to-consumer marketing campaign
Revenue
$1.91M
Diluted EPS
$-1.42
Gross margin
77.7%
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-03-07
Phathom Pharmaceuticals, Inc. Q4 FY2023 Earnings Call
Confident tone
VOQUEZNA launch progress
Launch variability and risk
Demand versus filled prescriptions
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-10
Phathom Pharmaceuticals, Inc. Q3 FY2020 Earnings Call
Results not yet reported
Audio
Transcript
Slides
8-K10-Q
Showing 1–15 of 15 earnings calls
Key facts
CIK
1783183
CUSIP
71722W107
13F (30d)
22 filings
22 filers
Visit website
Investor relations